151 related articles for article (PubMed ID: 38575671)
21. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.
Benedetti D; Tissino E; Pozzo F; Bittolo T; Caldana C; Perini C; Martorelli D; Bravin V; D'Agaro T; Rossi FM; Bomben R; Santinelli E; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Poeta G; Rossi D; Gaidano G; Dal Bo M; Gattei V; Zucchetto A
Leukemia; 2018 Mar; 32(3):654-662. PubMed ID: 28935990
[TBL] [Abstract][Full Text] [Related]
22. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M
Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855
[TBL] [Abstract][Full Text] [Related]
23. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
24. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
Xu J; Zhou P; Wang W; Sun A; Guo F
J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
[TBL] [Abstract][Full Text] [Related]
25. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
Mansouri L; Noerenberg D; Young E; Mylonas E; Abdulla M; Frick M; Asmar F; Ljungström V; Schneider M; Yoshida K; Skaftason A; Pandzic T; Gonzalez B; Tasidou A; Waldhueter N; Rivas-Delgado A; Angelopoulou M; Ziepert M; Arends CM; Couronné L; Lenze D; Baldus CD; Bastard C; Okosun J; Fitzgibbon J; Dörken B; Drexler HG; Roos-Weil D; Schmitt CA; Munch-Petersen HD; Zenz T; Hansmann ML; Strefford JC; Enblad G; Bernard OA; Ralfkiaer E; Erlanson M; Korkolopoulou P; Hultdin M; Papadaki T; Grønbæk K; Lopez-Guillermo A; Ogawa S; Küppers R; Stamatopoulos K; Stavroyianni N; Kanellis G; Rosenwald A; Campo E; Amini RM; Ott G; Vassilakopoulos TP; Hummel M; Rosenquist R; Damm F
Blood; 2016 Dec; 128(23):2666-2670. PubMed ID: 27670424
[TBL] [Abstract][Full Text] [Related]
26. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Herishanu Y; Pérez-Galán P; Liu D; Biancotto A; Pittaluga S; Vire B; Gibellini F; Njuguna N; Lee E; Stennett L; Raghavachari N; Liu P; McCoy JP; Raffeld M; Stetler-Stevenson M; Yuan C; Sherry R; Arthur DC; Maric I; White T; Marti GE; Munson P; Wilson WH; Wiestner A
Blood; 2011 Jan; 117(2):563-74. PubMed ID: 20940416
[TBL] [Abstract][Full Text] [Related]
27. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Vaisitti T; Gaudino F; Ouk S; Moscvin M; Vitale N; Serra S; Arruga F; Zakrzewski JL; Liou HC; Allan JN; Furman RR; Deaglio S
Haematologica; 2017 Nov; 102(11):1878-1889. PubMed ID: 28860341
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
29. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Xia M; Luo TY; Shi Y; Wang G; Tsui H; Harari D; Spaner DE
J Immunol; 2020 Nov; 205(10):2629-2639. PubMed ID: 33067379
[TBL] [Abstract][Full Text] [Related]
30. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
31. NOD2 silencing promotes cell apoptosis and inhibits drug resistance in chronic lymphocytic leukemia by inhibiting the NF-κB signaling pathway.
Zheng C; Zhu Z; Weng S; Zhang Q; Fu Y; Cai X; Liu Z; Shi Y
J Biochem Mol Toxicol; 2023 Dec; 37(12):e23510. PubMed ID: 37700718
[TBL] [Abstract][Full Text] [Related]
32. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Gutjahr JC; Szenes E; Tschech L; Asslaber D; Schlederer M; Roos S; Yu X; Girbl T; Sternberg C; Egle A; Aberger F; Alon R; Kenner L; Greil R; Orian-Rousseau V; Hartmann TN
Blood; 2018 Mar; 131(12):1337-1349. PubMed ID: 29352038
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
34. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
35. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
[TBL] [Abstract][Full Text] [Related]
36. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
37. Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.
Rey-Barroso J; Munaretto A; Rouquié N; Mougel A; Chassan M; Gadat S; Dewingle O; Poincloux R; Cadot S; Ysebaert L; Quillet-Mary A; Dupré L
Haematologica; 2024 Mar; 109(3):809-823. PubMed ID: 37381758
[TBL] [Abstract][Full Text] [Related]
38. Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.
Hahn M; Bürckert JP; Luttenberger CA; Klebow S; Hess M; Al-Maarri M; Vogt M; Reißig S; Hallek M; Wienecke-Baldacchino A; Buch T; Muller CP; Pallasch CP; Wunderlich FT; Waisman A; Hövelmeyer N
Leukemia; 2018 Jan; 32(1):72-82. PubMed ID: 28566736
[TBL] [Abstract][Full Text] [Related]
39. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
40. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
